Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of SGN-MesoC2 in Advanced Solid Tumors
NCT06466187 · View on ClinicalTrials.gov ↗
Study Summary
This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts of your body, it's called metastatic. When a cancer has gotten so big it can't easily be removed or has spread to other parts of the body, it is called unresectable. These types of cancer are harder to treat. Patients in this study must have cancer that has come back or did not get better with treatment. Patients must have a solid tumor cancer that can't be treated with standard of care drugs. This clinical trial uses an experimental drug called PF-08052666/SGN-MesoC2. PF-08052666/SGN-MesoC2 is a type of antibody-drug conjugate (ADC). ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells. This study will have 3 parts. Part A and Part B of the study will find out how much PF-08052666/SGN-MesoC2 should be given to participants. Part C will use the information from Parts A and B to see if PF-08052666/SGN-MesoC2 is safe and if it works to treat solid tumor cancers.
Conditions Studied
Interventions
- DRUG PF-08052666
Study Locations (20)
Kansas
- The University of Kansas Clinical Research Center — Fairway
- The University of Kansas Hospital Cambridge North Tower A — Kansas City
- The University of Kansas Hospital — Kansas City
- The University of Kansas Medical Center Medical Office Building — Kansas City
- The University of Kansas Cancer Center - Indian Creek Campus — Overland Park
- The University of Kansas Cancer Center - Westwood — Westwood
- The University of Kansas Cancer Center, Investigational Drug Services — Westwood
Alabama
- University of Alabama at Birmingham — Birmingham
- The University of Alabama at Birmingham — Birmingham
- University of Alabama at Birmingham — Birmingham
- The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham — Birmingham
Tennessee
- Sarah Cannon Research Institute - Pharmacy — Nashville
- SCRI Oncology Partners — Nashville
Utah
- START Mountain Region, LLC — Salt Lake City
- START Mountain Region — West Valley City
Ontario
- University Health Network — Toronto
- University Health Network, Princess Margaret Cancer Centre — Toronto
North Carolina
- Atrium Health Wake Forest Baptist — Winston-Salem
Texas
- START San Antonio, LLC — San Antonio
Quebec
- The Research Institute of the McGill University Health Centre — Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2024-08-02 |
| Est. Completion | 2029-05-01 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06466187
The ClinicalTrials.gov registry entry for NCT06466187 describes a study currently listed as active not recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, a wholly owned subsidiary of Pfizer, which has 51 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 7 conditions, with Carcinoma, Non-Small-Cell Lung appearing as the primary indexed condition, and to 1 intervention — of which PF-08052666 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06466187 reports 20 study locations spanning 8 distinct geographic areas — top geographies include Kansas, Alabama, Tennessee. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06466187 about?
NCT06466187 is a clinical study titled "A Study of SGN-MesoC2 in Advanced Solid Tumors". This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of your blood. Once tumors have grown bigger in one place but haven't spread, they're called locally advanced. If your cancer has spread to other parts o...
What is the current status of trial NCT06466187?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2024-08-02. Estimated completion is 2029-05-01.
What conditions does trial NCT06466187 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small-Cell Lung, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Ovarian Neoplasms. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06466187?
The interventions under investigation include: PF-08052666 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06466187?
This trial is sponsored by Seagen, a wholly owned subsidiary of Pfizer, which has 51 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06466187 being conducted?
This trial has 20 study locations across Alabama, Kansas, North Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.